GAGEOMACROLACTIN 1


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YMTVOMWYIOREGF-PDCYHRRVSA-N
Smiles	C[C@@H]1CCC\C=C\C=C\[C@H](O)C[C@@H](O)C[C@@H]2O[C@@H]2\C=C\[C@@H](O)C\C=C\C=C/C(=O)O1
InChI	InChI=1S/C24H34O6/c1-18-10-6-3-2-4-7-12-20(26)16-21(27)17-23-22(30-23)15-14-19(25)11-8-5-9-13-24(28)29-18/h2,4-5,7-9,12-15,18-23,25-27H,3,6,10-11,16-17H2,1H3/b4-2+,8-5+,12-7+,13-9-,15-14+/t18-,19+,20+,21-,22-,23+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H34O6
Molecular Weight	418.52
AlogP	2.53
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	0.0
Polar Surface Area	99.52
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	30.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) NUGC3 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) PC3 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) NCI-H23 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) HCT15 cell	Homo sapiens	30.0 ug.mL-1
Cytotoxicity against Homo sapiens (human) ACHN cells	Homo sapiens	30.0 ug.mL-1
Antibacterial activity against Escherichia coli	Escherichia coli	40.0 nM
Antibacterial activity against Bacillus subtilis	Bacillus subtilis	30.0 nM
Antifungal activity against Saccharomyces cerevisiae assessed as inhibition of mycelial growth	Saccharomyces cerevisiae	None
Antifungal activity against Aspergillus niger assessed as inhibition of mycelial growth	Aspergillus niger	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2289503
PubChem	71583780

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).